AURINIA PHARMACEUTICALS INC

AUPHNASDAQ

🏆 #1646 by market capEarnings Nov 3US Equity

$410.91▼ $15.12 (−3.68%)

Simulated price

1h—

24h▼ 3.7%

7d▲ 2606.9%

14d▲ 2608.7%

30d▲ 2464.2%

1y▲ 3526.7%

🏦Market Cap

$1.99B

Small Cap

📈Revenue Growth (YoY)

+20.6%

Healthy

📊Gross Margin

89.7%

High

💵FCF Margin

55.9%

Strong

⚖️P/S Ratio

6.7x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $409.10 – $417.33
52-Week Range: $10.34 – $19.25
Volume: $3.87B
Avg Volume: $3.42B
Shares Outstanding: 128.6M
Next Earnings: Sep 7, 2026

Fundamentals Snapshot

Annual Revenue: $283M
Last Q Revenue: $83M
P/E Ratio: 6.7
P/S Ratio: 6.7x
EPS (TTM): $2.17
Dividend Yield: —

Why Investors Own AUPH

✓High-growth profile — revenue up +47.3% YoY with expanding US Equity exposure.
✓Healthy economics — 34% gross margin and 25% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$283M▲ +49.0% YoY

Gross Margin (TTM)

33.7%▲ +1.8% YoY

Operating Income (TTM)

$52M▲ +49.0% YoY

Free Cash Flow (TTM)

$70M▲ +49.0% YoY

About AURINIA PHARMACEUTICALS INC

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

🦦